These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 28109402)

  • 1. Frontline treatment of acute myeloid leukemia in adults.
    Tamamyan G; Kadia T; Ravandi F; Borthakur G; Cortes J; Jabbour E; Daver N; Ohanian M; Kantarjian H; Konopleva M
    Crit Rev Oncol Hematol; 2017 Feb; 110():20-34. PubMed ID: 28109402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
    Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Acute myeloid leukemia].
    Döhner K; Paschka P; Döhner H
    Internist (Berl); 2015 Apr; 56(4):354-63. PubMed ID: 25787321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents.
    Tallman MS
    Hematology Am Soc Hematol Educ Program; 2005; ():143-50. PubMed ID: 16304372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
    Roboz GJ; Ritchie EK; Curcio T; Provenzano J; Carlin R; Samuel M; Wittenberg B; Mazumdar M; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
    Cancer; 2008 Nov; 113(9):2504-11. PubMed ID: 18825661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
    Nakayama H; Tomizawa D; Tanaka S; Iwamoto S; Shimada A; Saito AM; Yamashita Y; Moritake H; Terui K; Taga T; Matsuo H; Kosaka Y; Koh K; Hosoi H; Kurosawa H; Isoyama K; Horibe K; Mizutani S; Adachi S
    Pediatr Int; 2017 Oct; 59(10):1046-1052. PubMed ID: 28771903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current and new therapeutic strategies in acute myeloid leukemia].
    Naito K; Ohnishi K
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):292-6. PubMed ID: 15791811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
    Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
    Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
    Borthakur G; Kantarjian H; Wang X; Plunkett WK; Gandhi VV; Faderl S; Garcia-Manero G; Ravandi F; Pierce S; Estey EH
    Cancer; 2008 Dec; 113(11):3181-5. PubMed ID: 18932257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cure of leukemia through the optimist's prism.
    Kantarjian HM; Jain N; Garcia-Manero G; Welch MA; Ravandi F; Wierda WG; Jabbour EJ
    Cancer; 2022 Jan; 128(2):240-259. PubMed ID: 34614211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?
    McCurdy SR; Luger SM
    Haematologica; 2021 Oct; 106(10):2544-2554. PubMed ID: 34320781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
    Park H; Youk J; Kim I; Yoon SS; Park S; Lee JO; Bang SM; Koh Y
    Ann Hematol; 2016 Oct; 95(11):1777-86. PubMed ID: 27539617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
    Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
    Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
    Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
    Martin MG; Augustin KM; Uy GL; Welch JS; Hladnik L; Goyal S; Tiwari D; Monahan RS; Reichley RM; Cashen AF; Stockerl-Goldstein K; Westervelt P; Abboud CN; Dipersio JF; Vij R
    Am J Hematol; 2009 Nov; 84(11):733-7. PubMed ID: 19806665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
    Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.
    Montillo M; Ricci F; Tedeschi A; Cafro AM; Nosari AM; Nichelatti M; Marbello L; Morra E
    Leuk Res; 2009 Aug; 33(8):1072-8. PubMed ID: 19187960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.
    Guolo F; Minetto P; Clavio M; Miglino M; Lemoli RM; Gobbi M
    Biosci Trends; 2017 Mar; 11(1):110-114. PubMed ID: 28123146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.